Preliminary data indicate myelin oligodendrocyte glycoprotein (MOG)-CAR-Tregs secrete remyelination-promoting factors, positioning them as a potential therapeutic approach for multiple sclerosis (MS) where neuroprotection is paramount (83). Here, MOG is linked to myeloid sarcoma.